期刊文献+

AIH患者外周血PD-1表达与肝脏炎症活动度的相关性分析

Expression of PD-1 on Peripheral Blood T Cells and the Correlation With Liver Inflammatory Activity in Patients With Autoimmune Hepatitis
下载PDF
导出
摘要 目的研究细胞表面程序性死亡受体1(PD-1)与肝脏病变程度的相关性。方法收集43例AIH患者,并选择18例健康体检者为对照组。采用流式细胞术检测外周血CD4^+、CD8^+T细胞中PD-1的表达。结果 AIH组外周血CD4^+、CD8^+T细胞表达PD-1的细胞百分比高于对照组(P<0.05);AIH活动期组外周血CD4^+、CD8^+T细胞表达PD-1的细胞百分比高于缓解期组和对照组(P<0.05)。外周血CD4^+、CD8^+T细胞PD-1的表达在AIH患者病理重度炎症组、轻度炎症组及缓解期逐渐下降(P<0.05)。结论 PD-1可作为评判肝脏炎症活动度的参考指标之一。 Objective To investigate the correlation of programmed cell death receptor 1(PD-1)with liver inflammatory activity. Methods The percentages of PD-1 on CD4-+,CD8-+T lymphocytes in peripheral blood of patients with AIH(n=43)and healthy controls(n=18)was determined by flow cytometry. Results We found that the percentages of PD-1 on CD4-+,CD8-+T lymphocytes in peripheral blood of patients with AIH were higher than the healthy controls. The percentages of PD-1 on CD4-+,CD8-+T lymphocytes peripheral blood in activity stage,remission stage and the control group were gradually declined. The expression of PD-1 in severe inflammation,mild inflammation and remission stage were gradually decline,and PD-1 expression was a positively correlated with inflammation grading of hepatitis tissues. Conclusion PD-1 can be used as a reference index evaluation of liver inflammatory activity.
出处 《中国卫生标准管理》 2016年第2期34-36,共3页 China Health Standard Management
基金 福州市卫生系统科技计划项目(2014-S-w21)
关键词 自身免疫性肝炎 PD-1 T细胞 肝脏炎症活动度 Autoimmune hepatitis Programmed cell death receptor 1 T cells Liver inflammatory activity
  • 相关文献

参考文献3

二级参考文献32

  • 1孔晓东.药物经济学:概念、方法和应用[J].国外医学(药学分册),1994,21(1):13-18. 被引量:429
  • 2艾伟鹏,方红城.三种他汀类药物治疗高脂血症的经济学分析[J].现代医药卫生,2005,21(10):1199-1200. 被引量:6
  • 3Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 4慢性乙型肝炎防治指南[J].中华内科杂志,2006,45(2):162-170. 被引量:185
  • 5罗生强,张玲霞.2007年美国慢性乙型肝炎诊治推荐意见简介[J].中华肝脏病杂志,2007,15(6):477-480. 被引量:58
  • 6Liaw Y F, Gane E, Leung N,et al.2-year globe trial results:telbivu- dine is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 2009,136 ( 2 ) : 486-495.
  • 7Hou J, Yin Y K,Xu D, et al.Telbivudine versus lamivudine in Chi- nese patients with chronic hepatitis B:results at 1 year of a random- ized, double-blind trial[J]. Hepatology, 2008,47 ( 2 ) : 447-454.
  • 8Gane E J,Wang Y, Liaw Y F,et al.Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B[J].Liv- er Int, 2011,31 (5) : 676-684.
  • 9任红,贾继东,侯金林,等.替比夫定治疗中国慢性乙型肝炎患者第3年疗效和安全性[D].中华医学会第十四次全国病毒性肝炎及肝病学术会议.2009:125-126.
  • 10Zeuzem S,Gane E,Liaw Y F,et a|.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivu- dine treatment of chronic hepatitis B[J].J Hepatol,2009,51 ( 1 ) : 11-20.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部